Navigation Links
Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
Date:12/16/2008

NEW YORK, LONDON and HAMILTON, Bermuda, Dec. 16 /PRNewswire/ --Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") announced today that the databases have been locked and preliminary analyses completed on the two double-blinded studies of XERECEPT(R) (corticorelin acetate), as a treatment for peritumoral brain edema, as well as an initial database lock on the open-label study of XERECEPT's long-term safety and efficacy.

The results of these studies are the subject of several abstract submissions for the American Society of Clinical Oncology (ASCO) annual meeting in May 2009, as well as the American Association of Cancer Research annual meeting (AACR) in April 2009. In conformance with the requirements of both ASCO and AACR, XERECEPT(R) datawill be published only after presentation at these meetings.

Celtic Pharma has also retained a top-tier investment bank to serve as its financial advisor in the planned sale in 2009 of Neutron Holdings Limited and its geographical subsidiaries who are the owners of the worldwide commercial rights to XERECEPT(R).

"We believe that the trial data we now have in hand indicate the efficacy and long term safety of Xerecept as a treatment for cerebral edema associated with primary and metastatic brain tumors, permitting substantial reductions or elimination of cortico-steroid dosing in this patient population, and that Xerecept has the potential to become part of the generally accepted standard of care for these patients." said Stephen Evans-Freke, Managing General Partner of Celtic Pharma. "We believe we have built substantial value in Xerecept(R) and we look forward to achieving superior returns for our investors through the sale of this important program in 2009." said John Mayo, co-Managing General Partner of Celtic Pharma.

About Celtic Pharmaceutical Holdings L.P.

Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) is a global private equity investment firm focused on the biotechnology and pharmaceutical industries. Celtic Pharma was founded by Stephen Evans-Freke and John Mayo, CBE and is based in Bermuda, with offices in New York and London. Celtic Pharma acquires and invests in late stage pharmaceutical programs and manages these programs through their development to regulatory approval. Celtic Pharma's aim is to bridge the gap between the established pharmaceutical companies' new product pipeline crisis and the biotech industry's capital drought. For further information, please visit Celtic Pharma's website at www.celticpharma.com.

Forward-Looking Statements

Certain statements in this press release are not historical facts, including statements that are preceded by, or followed by, or that include words such as "may," "expect," "anticipate," "believe," or "plan," or similar statements, are forward-looking statements that involve risks and uncertainties, including risks relating to the results of the clinical trials for XERECEPT(R) and the ability of Celtic Pharma or Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") to obtain regulatory approval for XERECEPT(R), as well as other risks detailed from time to time in NTI's Securities and Exchange Commission filings. Copies of these filings are available from NTI upon request. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of release. We disclaim, however, any intent to update these forward looking statements.


'/>"/>
SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. Pharmasset Reports Fiscal Year End 2008 Financial Results
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
8. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
9. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
10. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
11. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):